Antidepressant-Induced Sexual Dysfunction: A comparison between Duloxetine and Escitalopram
|
|
- Abner Hill
- 5 years ago
- Views:
Transcription
1 Original Article Antidepressant-Induced Sexual Dysfunction: A comparison between Duloxetine and Escitalopram Anurag Jhanjee*, Pankaj Kumar*, Neeraj Kumar Gupta** *Department of Psychiatry, UCMS & GTB Hospital, Delhi, University of Delhi **Department of Psychiatry & Drug De-addiction Centre, Lady Hardinge Medical College, New Delhi , India ABSTRACT Background: Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) have the potential to produce delayed ejaculation in men, delayed orgasm or anorgasmia in women and decreased libido that is independent of the gender. The occurrence of medication-associated sexual dysfunction increases the likelihood of medication non-compliance (or non-adherence) in patients, which may contribute to untreated depression and/or disease relapse. Materials & Methods: 60 patients with diagnosis of Depressive episode (in remission at the time of study), divided into 2 groups of 30 patients taking Duloxetine and the remaining 30 patients taking Escitalopram, were recruited on consecutive basis from the patients attending Psychiatry OPD of Lady Hardinge Medical College (LHMC). Each subject was rated on Arizona Sexual Experience Scale (ASEX) and the results obtained were statistically analyzed. Results: In the present study the average ASEX score obtained in the Escitalopram group (12.63) was found to be more than that in Duloxetine group (12.36), though this difference was not found to be statistically significant. Conclusions: These results illustrate that antidepressant-induced sexual dysfunction is reported frequently by patients taking SSRIs or SNRIs. Our study did not find any significant difference between escitalopram and duloxetine with respect to their sexual dysfunction profile but in view of the limitations of our study there is need for further research in this domain of psychopharmacology. Key words: Escitalopram, duloxetine, Arizona Sexual Experience Scale (ASEX) Sexual dysfunction has been reported to occur in approximately 30-70% of patients receiving antidepressant medications. Package insert data for selective serotonin reuptake inhibitors (SSRIs) and other newer antidepressants show rates of sexual dysfunction as a result of antidepressant use ranging from 0% to about 15% depending of the type of sexual dysfunction and the SSRI studied, with a mean rate of less than 10%. Antidepressant-induced sexual dysfunction is common but underreported. For instance, only 14.2% of depressed patients taking selective serotonin reuptake inhibitors (SSRIs) for depression spontaneously report sexual complaints; however, if queried directly, nearly 60% of patients report sexual complaints. 1 Using standardized instruments, such as the Arizona Sexual Experiences Scale (ASEX) 2 and the Changes in Sexual Functioning Questionnaire (CSFQ) 1, and asking phase-specific questions may facilitate the clinicians assessment of patients sexual dysfunction. There are a number of patient s risk factors for sexual dysfunction. These include age (being 50 years old or older), having less than a college level education, not being employed full-time, tobacco use (6-20 times per day), a prior history of 89
2 DELHI PSYCHIATRY JOURNAL Vol. 13 No.1 APRIL 2010 antidepressant-induced sexual dysfunction, a history of little or no sexual enjoyment, and considering sexual functioning as not or only somewhat important. 3 Gender, race, and duration of treatment, in contrast, do not appear to predict sexual dysfunction. Broadly speaking, there are 3 stages of sexual functioning [Stage 1: interest and desire (libido), Stage 2: physiologic arousal, and Stage 3: orgasm] and five primary neurotransmitters, dopamine (Stage 1), nitric oxide and acetylcholine (Stage 2), serotonin(stage 2 and 3), and norepinephrine (Stage 3), which are believed to play the most crucial roles in antidepressant-associated sexual dysfunction. 4 In general, the tricyclic antidepressants (TCAs) and the monoamine oxidase inhibitors (MAOIs) seem to affect all stages of sexual functioning 5. For sexual dysfunction related to SSRI use, difficulties seem to occur most commonly in relation to Stages 2 and 3 due to their ability to enhance neurotransmission of serotonin. Although major depression has been associated with the occurrence of sexual dysfunction, many antidepressant agents can exacerbate or induce this problem. Therefore it is sometimes difficult to determine whether sexual difficulties in a medicated individual result from their psychiatric condition(s) or from the medications being used to treat them. Angst et al 6, examined 591 males and females in the age group of years in the general population to determine the prevalence of sexual problems in depressed individuals. By comparing those subjects with depression to non-depressed subjects they found over a two-fold difference in the prevalence of sexual dysfunction (50% vs 24% respectively). The subjects with depression were subsequently stratified based on whether they were currently being treated for their depression. This analysis showed that 62% of those receiving pharmaco-therapy reported some sexual dysfunction, compared to 45% of those untreated, and 24% in the non-depressed controls. In one of the largest prospective studies of antidepressant-associated sexual dysfunction, by Montejo et al 7, it was found that 59.1 % of the patients experienced some form of sexual dysfunction after antidepr essant initiation. However, only 20.2% of patients reported their problem spontaneously and the remaining 79.8% would have gone undiscovered. Antidepressants with the highest r ates of dysfunction were citalopram (72.7%),paroxetine (70.7%), and venlafaxine (67.3%). Mirtazapine had a lower rate of dysfunction (24.4%) than the SSRIs as did nefazodone (8.0%), amineptine (6.9%), and moclobemide (3.9%). The most common adverse sexual effects of the SSRIs and venlafaxine were decreased libido and delayed orgasm. Paroxetine was associated with significantly higher rates of erectile dysfunction and decreased vaginal lubrication (p < 0.05) as compared to the other antidepressants. Males had a higher rate of dysfunction than females (62.4% vs. 56.9%), but females experienced more severe decreases in libido, delayed orgasm, and anorgasmia (p < 0.05). Twenty-seven percent of the patients showed good tolerance to the sexual side effects, 34.5% accepted it with some objection, and 38.3% considered it unacceptable and suggested that this significantly affected their desire to continue therapy with their current medication. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) and Duloxetine is a Serotonin Norepinephrine Reuptake inhibitor (SNRI). Studies have demonstrated sexual dysfunction rates of 57 % to 73 % for SSRIs ( Montejo et al, 2001) 7 and 43 % for SNRIs ( Clayton AH, Pradko JF et al,2002 ). 3 Pooled data from 6 studies of duloxetine revealed that for patients without sexual dysfunction at baseline, the incidence of sexual dysfunction during the acute phase of treatment was significantly higher among patients receiving duloxetine than among those receiving placebo (46.4% vs. 28.8%) 8. In an 8-month, randomized double blind, placebocontrolled study of duloxetine and escitalopram, 114 of the 634 patients had no sexual dysfunction at baseline (based on the 14-itemChanges in Sexual Functioning Questionnaire). Of these, 33% of the patients receiving duloxetine, 43.6% of those receiving escitalopram and 25% of those receiving placebo reported sexual dysfunction at the end of 8 weeks of treatment. After 12 weeks, there were no statistically significant differences between drugs; however, Major Depressive Disorder (MDD) outcome (regardless of treatment) had a significant impact on improvement in global sexual functioning. 9 The occurrence of medication-associated 90
3 sexual dysfunction increases the likelihood of medication non-compliance (or non adherence) in the patients, which may contribute to untreated depression and/or disease relapse. The present study aims to find out and compare the sexual dysfunction profile in patients taking escitalopram and duloxetine as this information is clinically relevant in determining the probability of patient s noncompliance and in selecting the most suitable antidepressant for the patient Materials and methods Sixty subjects with diagnosis of Depressive episode (ICD-10 DCR), and who were in remission at the time of the study (Hamilton Depression Rating Scale (17 item ) {HDRS total score < 7} were selected from the patients attending the outpatient services of department of Psychiatry, Lady Hardinge Medical College and Associated Smt. Sucheta Kriplani Hospital on consecutive basis such that there were two groups - the first group comprising of 30 patients taking Escitalopram and the second group comprising of 30 patients taking Duloxetine. Subjects that were excluded from the study included those suffering from any medical or surgical conditions, those with a history of co morbid substance abuse, pregnant and lactating women, and those suffering from any psychiatric disorder other than depression in order to ensure that results of our study were not influenced by these confounding factors. Arizona Sexual Experience Scale (ASEX) 2 was administered on subjects in both the groups after obtaining informed consent. ASEX is a user friendly five-item rating scale that quantifies sex drive, arousal, vaginal lubrication/ penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with higher scores indicating more sexual dysfunction. ASEX has shown an excellent internal consistency and reliability, and strong test retest reliability in patients with depression (McGahuey et al., 2000) 2. Although its sensitivity to change has not been formally tested, data from its extensive use in interventional studies suggest that the ASEX can also effectively measure changes in sexual function over time (McGahuey et al., 2000) 2. The results of the study were statistically analyzed using Microsoft Excel. Results There were a total of 16 female and 14 male subjects in the Escitalopram group, while in the duloxetine group; there were 21 female and 9 male subjects. The age distribution in the two groups is tabulated below: Age distribution Number of subjects Age group Escitalopram Duloxetine (in years) group group Age distribution Age Range Series1 Series2 The mean age of escitalopram group was (S.D- 7.60) and that of the duloxetine group was 36.6 (S.D- 9.75), on analysis there was no statistical difference between the mean ages of the two groups. Comparison of age distribution: Group Mean ± S.D. p value Escitalopram Group ± 7.60 Duloxetine Group 36.6 ± The two groups were compared with respect to average total score on HDRS (17 item) and as shown below the difference between the two groups was not found to be statistically significant. Number of subjects Sex distribution 1 2 Escita lopra m Dul ox e tine Male Fem ale 91
4 DELHI PSYCHIATRY JOURNAL Vol. 13 No.1 APRIL 2010 Comparison of average HDRS score Group Mean ± S.D. p value Escitalopram Group 5.56 ± Duloxetine Group 5.66 ± In the present study the average ASEX score obtained in the Escitalopram group (12.63) was found to be more than that in Duloxetine group (12.36), but it was not found to be statistically significant. HDRS average score Av HDRS Comparison of average ASEX scores: Variable Mean ± S.D P Value Net a Sex Score Escitalopram Group ± Duloxetine Group ± A Sex Item 1 Escitalopram Group 2.6 ± Duloxetine Group 2.43 ± A Sex Item 2 Escitalopram Group 2.33 ± Duloxetine Group 2.46 ± A Sex Item 3 Escitalopram Group 2.36 ± Duloxetine Group 2.26 ± A Sex Item 4 Escitalopram Group 2.53 ± Duloxetine Group 2.43 ± A Sex Item 5 Escitalopram Group 2.83 ± Duloxetine Group 2.76 ± Escitalo Duloxetine Scores on individual items between the two groups was compared and here also no statistically significant difference was found. In both the groups maximum individual scores was obtained on the item Are your orgasms satisfying? Clinical sexual dysfunction (ASEX total score>18) was found in 3 subjects (1 male and 2 females) out of 60 subjects; Two out of three subjects belonging to the Escitalopram group. ASEX average score Escitalo Av ASEX Duloxetine Discussion In the present study only 5 % of the subjects showed clinical sexual dysfunction which is less than the reported incidence of sexual dysfunction associated with antidepressant therapy of 22% to 43% (Clayton AH et.al, 2002) 3.As regards the sexual drive, 10% subjects in the Escitalopram group reported somewhat weak as compared 3.3% subjects in duloxetine group. In the Escitalopram group, 20% reported some dissatisfaction in orgasms as compared to 13.3% in the Duloxetine group. These results are consistent with studies showing greater sexual dysfunction with escitalopram than Duloxetine (Kornstein S, Mallinckrodt C et.al, 2007) 9. As regards the total ASEX score, there was no statistically significant difference between the two groups. The results of our study show that antidepressant-induced sexual dysfunction is a common problem in the depressed patients, though scarcely repor ted. Using standardized instruments, such as the Arizona Sexual Experiences Scale (ASEX) 2 and the Changes in Sexual Functioning Questionnaire (CSFQ) 1, and asking phase-specific questions may facilitate the clinicians assessment of patients sexual dysfunction. Though our study did show that sexual dysfunction is reported by the patients taking
5 escitalopram and duloxetine, it did not find any statistically significant difference between these two groups. In view of the limitations of our study (as detailed below), there is an overbearing need for a well designed prospective study to find out if escitalopram and duloxetine differ significantly with respect to their sexual adverse effect profile. The answer to the above question is surely going to be one of the many considerations that will influence the choice of the most appropriate antidepressant for our patients. Limitations of the present study Sample size of 30 appears inadequate for a comprehensive insight into the domain of antidepressant-induced sexual dysfunction and as such a larger sample will prove to be more useful. Our study was cross-sectional in design, a better approach to decipher the adverse impact of antidepressants on patient s sexual functioning would include a careful follow up of the patient at regular intervals as this will help in finding out how the sexual adverse effects, as reported by patient, fare over a period of time. Conclusions Our study has shown that patients of depression (in remission at the time of study) taking either escitalopram (an SSRI) or duloxetine (an SNRI) reported sexual dysfunction as exhibited by high scores on ASEX. Though our study did not find statistically significant difference between sexual dysfunction profile of escitalopram and duloxetine, it is sincerely hoped that it will stimulate researchers to carry out studies in this domain of psychopharmacology. Further research is needed in the area of sexual dysfunctions associated with use of SSRIs and SNRIs as it may guide the selection of a suitable drug such that chances of treatment noncompliance and discontinuation are minimized and better treatment outcomes can be ensured. References 1. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): development, reliability, and validity. Psychopharmacol Bull 1997a; 33 : McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, Manber R. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Therap 2000; 26 : Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63 : Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19(1) : Zajecka J. Strategies for the treatment of antidepressant-related sexual dysfunction. J Clin Psychiatry 2001; 62 Suppl 3 : Angst J. Sexual problems in healthy and depressed persons. Int Clin Psychopharmacol 1998; 13 Suppl 6 : S Montejo AL, Llorca G, Izquierdo JA, Rico- Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3 : Hudson JI, Wohlreich MM, Kajdaz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol Clin Exp 2005; 20 : Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med 2007; 4 :
Objectives. Sexual dysfunction (SD) SD in the general population. Assessment of sexual functioning ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION
Objectives To appreciate the relationship between major depressive disorder, its treatment and sexual dysfunction To review the assessment of sexual function An approach to the clinical management of antidepressant
More informationObjectives. Introduction. SD in the general population. Sexual dysfunction (SD) ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION
Objectives ANTIDEPRESSANT-INDUCED SEXUAL DYSFUNCTION To appreciate the relationship between major depressive disorder, its treatment and sexual dysfunction To review the assessment of sexual function An
More informationTreatment-Emergent Sexual Dysfunction Related to Antidepressants. A Meta-Analysis. Alessandro Serretti, MD, PhD and Alberto Chiesa, MD
REVIEW ARTICLE Treatment-Emergent Sexual Dysfunction Related to Antidepressants A Meta-Analysis Alessandro Serretti, MD, PhD and Alberto Chiesa, MD Background: Sexual dysfunction (SD) is an important underestimated
More informationPrevalence of anxiety and depressive symptoms in men with erectile dysfunction
Prevalence of anxiety and depressive symptoms in men with erectile dysfunction K Pankhurst, MB ChB G Joubert, BA, MSc P J Pretorius, MB ChB, MMed (Psych) Departments of Psychiatry and Biostatistics, University
More informationMale Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: gmail.
RESEARCH ARTICLE Open Access Male Sexual Dysfunction in Psychiatric Illnesses Sujit Kumar Kar 1, Saranya Dhanasekaran 1 Correspondence: drsujita@gmail.com; saranya296@ gmail.com Full list of author information
More informationThe Impact of Mental Illness on Sexual Dysfunction
Balon R (ed): Sexual Dysfunction. The Brain-Body Connection. Adv Psychosom Med. Basel, Karger, 2008, vol 29, pp 89 106 The Impact of Mental Illness on Sexual Dysfunction Zvi Zemishlany Abraham Weizman
More informationJ Psychopharmacol OnlineFirst, published on September 18, 2008 as doi: /
J Psychopharmacol OnlineFirst, published on September 18, 2008 as doi:10.1177/0269881108096507 Original Papers Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg)
More informationGuilt Suicidality. Depression Co-Occurs with Medical Illness The rate of major depression among those with medical illness is significant.
1-800-PSYCH If you are obsessive-compulsive, dial 1 repeatedly If you are paranoid-delusional, dial 2 and wait, your call is being traced If you are schizophrenic, a little voice will tell you what number
More informationManagement of SSRI Induced Sexual Dysfunction. Serotonin Reuptake Inhibitors*
Management of SSRI Induced Sexual Dysfunction John J. Miller, M.D. Medical Director, Center for Health and WellBeing Exeter, NH Serotonin Reuptake Inhibitors* fluoxetine clomipramine sertraline paroxetine
More informationEffective Health Care
Number 7 Effective Health Care Comparative Effectiveness of Second- Generation Antidepressants in the Pharmacologic Treatment of Adult Depression Executive Summary Background Depressive disorders such
More information1 1 Evidence-based pharmacotherapy of major depressive disorder. Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A.
1 1 Evidence-based pharmacotherapy of major depressive disorder Michael J. Ostacher, Jeffrey Huffman, Roy Perlis, and Andrew A. Nierenberg Massachusetts General Hospital and Harvard University, Boston,
More informationDiagnosis & Management of Major Depression: A Review of What s Old and New. Cerrone Cohen, MD
Diagnosis & Management of Major Depression: A Review of What s Old and New Cerrone Cohen, MD Why You re Treating So Much Mental Health 59% of Psychiatrists Are Over the Age of 55 AAMC 2014 Physician specialty
More informationThis initial discovery led to the creation of two classes of first generation antidepressants:
Antidepressants - TCAs, MAOIs, SSRIs & SNRIs First generation antidepressants TCAs and MAOIs The discovery of antidepressants could be described as a lucky accident. During the 1950s, while carrying out
More informationA study to assess sexual dysfunction in patients with major depressive disorder
ISSN 2394-2053 (Print) ISSN 2394-2061 (Online) RNI: ASSENG/2016/70661 www.ojpas.com ORIGINAL ARTICLE Open Journal of Psychiatry & Allied Sciences A study to assess sexual dysfunction in patients with major
More informationDepression in Pregnancy
TREATING THE MOTHER PROTECTING THE UNBORN A MOTHERISK Educational Program The content of this program reflects the expression of a consensus on emerging clinical and scientific advances as of the date
More informationGuidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive
More informationEmotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses?
International Journal of Neuropsychopharmacology (2002), 5, 147 151. Copyright 2002 CINP DOI: 10.1017 S1461145702002870 Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit
More informationClinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant
The Clinical Significance of Anxiety Disorders and the DSM-5 Anxious Distress Specifier in Depressed Patients Clinical Significance of Anxiety in Depressed Patients Selecting an Antidepressant Rhode Island
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationPractice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association
Practice Guideline for the Treatment of Patients With Major Depressive Disorder: American Psychiatric Association Our clinical advisor adds updated advice on electroconvulsive therapy, transcranial magnetic
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationDepression and sexual dysfunction
David S Baldwin Community Clinical Sciences Research Division, Faculty of Medicine, Health and Biological Sciences, University of Southampton, Southampton, UK Correspondence to: Dr David S Baldwin, University
More informationCommon Side Effects of Psychiatric Medications
Common Side Effects of Psychiatric Medications Why This is a Big Deal Common Of patients taking an SSRI: 52% had three or more adverse effects 55% had 1 or more a lot or extremely bothersome Nonadherence:
More informationIntroduction to Drug Treatment
Introduction to Drug Treatment LPT Gondar Mental Health Group www.le.ac.uk Introduction to Psychiatric Drugs Drugs and Neurotransmitters 5 Classes of Psychotropic medications Mechanism of action Clinical
More informationAntidepressant Selection in Primary Care
Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.
More informationAssociation between 5HT2A polymorphism and selective serotonin re-uptake inhibitor (SSRI)-induced sexual desire disorder (SDD) among Malaysian women
bs_bs_banner Offi cial journal of the Pacifi c Rim College of Psychiatrists Asia Pacific Psychiatry ISSN 1758-5864 ORIGINAL ARTICLE Association between 5HT2A polymorphism and selective serotonin re-uptake
More informationVilazodone New Option for Depression
Human Journals Review Article November 2018 Vol.:13, Issue:4 All rights are reserved by Jisha Vijayan et al. Vilazodone New Option for Depression Keywords: Vilazodone, Safety, Efficacy, Major Depressive
More informationPresentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More information9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded
Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please
More informationJeffrey R. Bishop 1,2 *, Vicki L. Ellingrod 3, Michael Akroush 1 and Jessica Moline 3
human psychopharmacology Hum. Psychopharmacol Clin Exp 2009; 24: 207 215. Published online 9 February 2009 in Wiley InterScience (www.interscience.wiley.com).1006 The association of serotonin transporter
More informationSuicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative
Suicide Risk and Melancholic Features of Major Depressive Disorder: A Diagnostic Imperative Robert I. Simon, M.D.* Suicide risk is increased in patients with Major Depressive Disorder with Melancholic
More informationSymptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder B
Case 1:14-cv-01614-AJT-JFA Document 124-1 Filed 07/10/15 Page 81 of 247 PageID# 7765 Journal of Affective Disorders 89 (2005) 207 212 Brief report Symptoms following abrupt discontinuation of duloxetine
More informationJolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College
Jolene R. Bostwick, PharmD, BCPS, BCPP Clinical Associate Professor Associate Chair, Department of Clinical Pharmacy University of Michigan College of Pharmacy Clinical Pharmacist in Psychiatry University
More informationObjectives. Objectives. A practice review. 02-Nov-16 MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS
MAJOR DEPRESSIVE DISORDER: NEW DEVELOPMENTS AND PRACTICAL IMPLICATIONS Jon-Paul Khoo What is treatment resistance really? Database review 328 consecutive non-remitted MDD patients referred for private
More informationAntidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder
updated 2012 Antidepressants (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors) in children 6-12 years of age with depressive episode/disorder Q10: Are antidepressants (Tricyclic antidepressants
More informationDepression After Traumatic Brain Injury (TBI)
Depression After Traumatic Brain Injury (TBI) A resource for individuals with traumatic brain injury and their supporters This presentation is based on TBI Model Systems research and was developed with
More informationClass Update: Second Generation Antidepressant Medications. Dossier received: Yes
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDocument Title Pharmacological Management of Generalised Anxiety Disorder
Document Title Pharmacological Management of Generalised Anxiety Disorder Document Description Document Type Policy Service Application Trust Wide Version 1.1 Policy Reference no. POL 201 Lead Author(s)
More informationDepression & Anxiety in Adolescents
Depression & Anxiety in Adolescents Objectives 1) Review diagnosis of anxiety and depression in adolescents 2) Provide overview of evidence-based treatment options 3) Increase provider comfort level with
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationPLEASE SCROLL DOWN FOR ARTICLE
This article was downloaded by: [University of Texas Austin] On: 22 June 2009 Access details: Access Details: [subscription number 907743875] Publisher Routledge Informa Ltd Registered in England and Wales
More informationA Randomized, Placebo-Controlled, Crossover Study of Ephedrine for SSRI-Induced Female Sexual Dysfunction
Journal of Sex & Marital Therapy ISSN: 0092-623X (Print) 1521-0715 (Online) Journal homepage: http://www.tandfonline.com/loi/usmt20 A Randomized, Placebo-Controlled, Crossover Study of Ephedrine for SSRI-Induced
More informationAntidepressant Medication Strategies We ve Come a Long Way or Have We? Who Writes Prescriptions for Psychotropic Medications. Biological Psychiatry
Antidepressant Medication Strategies We ve Come a Long Way or Have We? Joe Wegmann, PD, LCSW The PharmaTherapist Joe@ThePharmaTherapist.com 504.587.9798 www.pharmatherapist.com Are you receiving our free
More informationJoel V. Oberstar, M.D. 1
Diagnosis and Treatment of Depressive Disorders in Children and Adolescents Joel V. Oberstar, M.D. CEO & Chief Medical Officer Adjunct Assistant Professor of Psychiatry University of Minnesota Medical
More informationQ: What are the gender differences in sexual dysfunction in adults with MS?
Mellen Center Approaches Sexual Dysfunction in MS Framework: Sexual dysfunction is a common symptom of MS. However, it is an underappreciated condition that often goes unreported by both the patient and
More informationDepression and the Role of L-methylfolate
Depression and the Role of L-methylfolate Depression is a chronic and recurrent disease affecting more than 18 million people in the United States, ranking it, along with heart disease, cancer and diabetes,
More informationMMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION
MMG004 GUIDELINES FOR THE USE OF HIGH DOSE VENLAFAXINE AND THE COMBINATION OF VENLAFAXINE AND MIRTAZAPINE IN THE TREATMENT OF DEPRESSION Page 1 of 13 Table of Contents Why we need this Guideline... 3 What
More informationOutline. Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly. Definitions
Outline Understanding Placebo Response in Psychiatry: The Good, The Bad, and The Ugly Michael E. Thase, MD Professor of Psychiatry Perelman School of Medicine University of Pennsylvania and Philadelphia
More informationEfficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence
Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence J. Craig Nelson, M.D., Kevin Delucchi, Ph.D., Lon S. Schneider, M.D. Objective: Second-generation
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationAdult Depression - Clinical Practice Guideline
1 Adult Depression - Clinical Practice Guideline 05/2018 Diagnosis and Screening Diagnostic criteria o Please refer to Attachment A Screening o The United States Preventative Services Task Force (USPSTF)
More informationA Retrospective Claims Analysis of Medication Adherence and. Persistence Among Patients Taking Antidepressants
A Retrospective Claims Analysis of Medication Adherence and Persistence Among Patients Taking Antidepressants for the Treatment of Major Depressive Disorder (MDD) Katelyn R. Keyloun A thesis submitted
More informationObsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care
Obsessive-Compulsive Disorder Clinical Practice Guideline Summary for Primary Care CLINICAL ASSESSMENT AND DIAGNOSIS (ADULTS) Obsessive-Compulsive Disorder (OCD) is categorized by recurrent obsessions,
More informationParoxetine: current status in psychiatry
Drug Profile Paroxetine: current status in psychiatry Chi-Un Pae and Ashwin A Patkar CONTENTS Clinical profile Expert commentary Five-year view Key issues References Affiliations Paroxetine is a selective
More informationPsychopharmacology. Psychopharmacology. Hamish McAllister-Williams Reader in Clinical. Department of Psychiatry, RVI
Regional Affective Disorders Service Psychopharmacology Northumberland, Tyne and Wear NHS Trust Hamish McAllister-Williams Reader in Clinical Psychopharmacology Department of Psychiatry, RVI Intro NOT
More informationFeature Article. Dimitry Francois, MD, FAPA; Ariana Mireille Levin, BS; Eric J. Kutscher, BA; and Babatunde Asemota, MBBS
Antidepressant-Induced Sexual Side Effects: Incidence, Assessment, Clinical Implications, and Management Dimitry Francois, MD, FAPA; Ariana Mireille Levin, BS; Eric J. Kutscher, BA; and Babatunde Asemota,
More informationPharmacological treatment of anxiety disorders where is
Pharmacological treatment of anxiety disorders where is the room for improvement? David S Baldwin, Professor of Psychiatry BAP Masterclass, 15 th April 2011 dsb1@soton.ac.uk Declaration of interests (last
More informationPHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES
PHYSICIAN REFERENCE ANTIDEPRESSANT DOSING GUIDELINES Table of Contents Print TABLE OF CONTENTS Drug Page Number Anafranil... 2 Asendin... 4 Celexa... 4 Cymbalta... 6 Desyrel... 8 Effexor...10 Elavil...14
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationPage 1 of 5. Policies Repository. Policy. Policy Description. Policy Guideline Inclusion
Page 1 of 5 Policies Repository Policy Title Policy Number Duloxetine (Cymbalta ) FS.CLIN.48 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line,
More informationAntidepressants Choosing the Right One
Antidepressants Choosing the Right One Dr Lim Boon Leng Consultant Psychiatrist Dr BL Lim Centre For Psychological Wellness #09-09, Gleneagles Medical Centre, 6 Napier Rd, S258499 www.psywellness.com.sg
More informationVolume 4; Number 5 May 2010
Volume 4; Number 5 May 2010 CLINICAL GUIDELINES FOR ANTIDEPRESSANT USE IN PRIMARY AND SECONDARY CARE Lincolnshire Partnership Foundation Trust in conjunction with Lincolnshire PACEF have recently updated
More informationQuick Guide to Common Antidepressants-Adults
Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa
More informationPrepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D.
Prepared by: Elizabeth Vicens-Fernandez, LMHC, Ph.D. Sources: National Institute of Mental Health (NIMH), the National Alliance on Mental Illness (NAMI), and from the American Psychological Association
More informationReducing the Anxiety of Pediatric Anxiety Part 2: Treatment
Reducing the Anxiety of Pediatric Anxiety Part 2: Treatment Lisa Lloyd Giles, MD Medical Director, Behavioral Consultation, Crisis, and Community Services Primary Children s Hospital Associate Professor,
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More informationOptimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE
Optimal Use of Antidepressants: Focusing on SNRI, NDRI and SSRE Chan-Hyung Kim, MD Severance Mental Health Hospital Institute of Behavioral Science in Medicine Diagnostic Criteria Pyramid Etiologic Pathophysiologic
More informationKing s Research Portal
King s Research Portal DOI: 10.1002/14651858.CD003382.pub3 Document Version Publisher's PDF, also known as Version of record Link to publication record in King's Research Portal Citation for published
More informationClinical Guideline / Formulary Document Pharmacy Department Medicines Management Services
Clinical Guideline / Formulary Document Pharmacy Department Medicines Management Services DEPRESSION Pharmacological Treatment of Depression NICE guidelines suggest the following stepped care model also
More informationMain exclusion criteria. therapy resistance, increased risk of suicide, MDD with psychotic features, substance abuse.
Web table A Trial characteristics Trial Primary publication? Clinical study report available?* Main inclusion criteria Main exclusion criteria Region Primary end point Secondary end point Time point of
More informationAverage dose zoloft for ocd and anxiety
Average dose zoloft for ocd and anxiety Gogamz Menu DESCRIPTION. Selective serotonin reuptake inhibitor (SSRI). Approved for depression, OCD, panic disorder, PTSD, premenstrual-dysphoric disorder (PMDD),
More informationTreat mood, cognition, and behavioral disturbances associated with psychological disorders. Most are not used recreationally or abused
Psychiatric Drugs Psychiatric Drugs Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally or abused Benzodiazepines
More informationKEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.
KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised
More informationAntidepressants. Dr Malek Zihlif
Antidepressants The optimal use of antidepressant required a clear understanding of their mechanism of action, pharmacokinetics, potential drug interaction and the deferential diagnosis of psychiatric
More informationMentoring Session: Participant Cases
Handout for the Neuroscience Education Institute (NEI) online activity: Mentoring Session: Participant Cases The Case: 55-year-old patient with depression and anxiety The Question: What to do when antidepressants
More informationAppendix C - Summary form
National Institute for Health and Clinical Excellence Appendix C - Summary form Single Techn Appraisal (STA) Agomelatine for the treatment of major depressive episodes Response to consultee and commentator
More informationDepression major depressive disorder. Some terms: Major Depressive Disorder: Major Depressive Disorder:
Depression major depressive disorder Oldest recognized disorder: melancholia It is a positive and active anguish, a sort of psychical neuralgia wholly unknown to normal life. - William James "I am now
More informationJournal of Medical Science & Technology
Original Article Journal of Medical Science & Technology Open Access Compare the Efficacy of Escitalopram and Amitriptyline to reduce the Suicidal Risk in Depression patients Baswaraj Munge 1, Bhavitha
More information10/27/09! Psychopharmacology 101 for the LADC! Disclosures! Lecture outline! Structural divisions of the nervous system!
Disclosures! Psychopharmacology 101 for the LADC! David A. Frenz, M.D.! Mental Health & Addiction Services! St. Josephʼs Hospital! I am employed by the HealthEast Care System! I do not have any financial
More informationComparison of the latency time of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors
Journal of Medicine and Medical Science Vol. 2(9) pp. 1085-1092, September 2011 Available online@ http://www.interesjournals.org/jmms Copyright 2011 International Research Journals Full Length Research
More informationPractice Matters: Screening and Referring Congregants with Major Depression
International Journal of Faith Community Nursing Volume 1 Issue 3 Article 6 October 2015 Practice Matters: Screening and Referring Congregants with Major Depression Kim Link Western Kentucky University
More informationEvidence-Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
SPECIAL ARTICLE Psychiatry & Psychology http://dx.doi.org/10.3346/jkms.2014.29.4.468 J Korean Med Sci 2014; 29: 468-484 -Based, Pharmacological Treatment Guideline for Depression in Korea, Revised Edition
More informationDisclaimer. The following report contains a description of the request, request specifications, and results from the modular program run(s).
Disclaimer The following report(s) provides findings from an FDA initiated query using its Mini Sentinel pilot. While Mini Sentinel queries may be undertaken to assess potential medical product safety
More informationPSYCHIATRIC DRUGS. Mr. D.Raju, M.pharm, Lecturer
PSYCHIATRIC DRUGS Mr. D.Raju, M.pharm, Lecturer PSYCHIATRIC DRUGS Treat mood, cognition, and behavioral disturbances associated with psychological disorders Psychotropic in nature Most are not used recreationally
More informationInternational Index of Erectile Function Questionnaire IIEF
International Index of Erectile Function Questionnaire IIEF Instructions: These questions ask about the effects your erections have had on your sex life, over the past 4 weeks. Please answer the following
More informationCommon Antidepressant Medications for Adults
(and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10
More informationResearch Article Substance Use Disorders in Men Presenting to a Psychosexual Clinic
ISRN Addiction, Article ID 486383, 4 pages http://dx.doi.org/10.1155/2014/486383 Research Article Substance Use Disorders in Men Presenting to a Psychosexual Clinic Ravi Philip Rajkumar Department of Psychiatry,
More informationMajor Depression and Anxiety in Adolescents and Adults
Major Depression and Anxiety in Adolescents and Adults Miggie Greenberg, M.D. Associate Professor of Psychiatry St. Louis University School of Medicine greenbml@slu.edu *NO DISCLOSURES* OBJECTIVES * Recognize
More informationWORLD PSYCHIATRIC ASSOCIATION. The next World Congress of the WPA will be organized in Cairo, September 10-15, 2005.
Meetings WORLD PSYCHIATRIC ASSOCIATION XIII World Congress of Psychiatry The next World Congress of the WPA will be organized in Cairo, September 10-15, 2005. Important, March 31st, 2005, is the deadline
More informationPharmacotherapy of OCD
Pharmacotherapy of OCD Michael Jenike, MD Professor of Psychiatry Harvard Medical School Founder, OCD Clinic & Research Unit Massachusetts General Hospital Founder, OCD Institute Mclean Hospital Jenike@comcast.net
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367
Vortioxetine for treating major depressive e episodes Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta367 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationReviews/Evaluations. Guidelines for Cost-Effective Use of Antidepressants. Current Utilization (January 1, 2002 through December 31, 2002)
Reviews/Evaluations Guidelines for Cost-Effective Use of Antidepressants Current Utilization (January 1, 2002 through December 31, 2002) OHP spent $54 million on antidepressant medications (Class 11) Drug
More informationPsychopharmacology: A Comprehensive Review
Psychopharmacology: A Comprehensive Review 1) The association between a chemical compound and its biological activity, pioneered by Bovet and colleagues in the 1930s is known as a) Symbiosis b) Structure-activity
More informationPharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder
840 Pharmacoeconomic evaluation of venlafaxine compared with citalopram in generalized anxiety disorder JINGJING ZHANG, HONGBING XU and ZHIQING CHEN Department of Psychological Medicine, Shanghai First
More informationDepression: Identification, Evaluation and Management in Primary Care
Depression: Identification, Evaluation and Management in Primary Care Primary Care Medicine: Update 2010 Rena K. Fox, M.D. Associate Professor of Clinical Medicine University of California, San Francisco
More informationNancy Kerner 1,2, Kristina D Antonio 1, Gregory H Pelton 1,2, Elianny Salcedo 2, Jennifer Ferrar 2, Steven P Roose 1,2 and DP Devanand 1,2
533536SMO0010.1177/2050312114533536SAGE Open MedicineKerner et al. research-article2014 Original Article SAGE Open Medicine An open treatment trial of duloxetine in elderly patients with dysthymic disorder
More informationSuitable dose and duration of fluvoxamine administration to treat depression
PCN Psychiatric and Clinical Neurosciences 1323-13162003 Blackwell Science Pty Ltd 572April 2003 1098 Dose and duration of fluvoxamine S. Morishita and S. Arita 10.1046/j.1323-1316.2002.01098.x Original
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationDepression and antidepressant prescribing in the elderly
REVIEW Depression and antidepressant prescribing in the elderly JAMES W HERRON AND ALISON MITCHELL SPL Depression in old age is common and associated with significant morbidity, yet it is frequently missed
More information